{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:51:07Z","timestamp":1781747467820,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical and Health Science Program of Zhejiang Province","award":["2025HY0486"],"award-info":[{"award-number":["2025HY0486"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genom Data"],"DOI":"10.1186\/s12863-026-01427-5","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:17:57Z","timestamp":1777547877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Yongning","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"crossref","unstructured":"Anca-Stanciu MB, Manu A, Olinca MV, Coroleuca C, Comandasu DE, Coroleuca CA, Maier C, Bratila E. Comprehensive review of endometrial cancer: new molecular and FIGO classification and recent treatment changes. J Clin Med. 2025;14.","DOI":"10.3390\/jcm14041385"},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","volume":"9","author":"W Cao","year":"2021","unstructured":"Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res. 2021;9:49.","journal-title":"Biomark Res"},{"key":"1427_CR3","doi-asserted-by":"crossref","unstructured":"Luvero D, Cundari GB, Ficarola F, Plotti F, Terranova C, Montera R, Bogani G, Silvagni A, Celoro F, Angioli R. Old issues and new perspectives on endometrial cancer therapy: how molecular characteristics are changing the therapeutic pathway. Cancers (Basel). 2024;16.","DOI":"10.3390\/cancers16101866"},{"key":"1427_CR4","doi-asserted-by":"crossref","unstructured":"Grau Bejar JF, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, Klein C, Le Formal A, Edmond E, Moreau M, Plat A, Gouy S, Maulard A, Pautier P, Michels J, Oaknin A, Colomba-Blameble E, Leary A. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. J Immunother Cancer. 2024;12.","DOI":"10.1136\/jitc-2024-009143"},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"975201","DOI":"10.3389\/fonc.2022.975201","volume":"12","author":"H van der Woude","year":"2022","unstructured":"van der Woude H, Hally KE, Currie MJ, Gasser O, Henry CE. Importance of the endometrial immune environment in endometrial cancer and associated therapies. Front Oncol. 2022;12:975201.","journal-title":"Front Oncol"},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"e4399","DOI":"10.1002\/pro.4399","volume":"31","author":"RM Buey","year":"2022","unstructured":"Buey RM, Fernandez-Justel D, Jimenez A, Revuelta JL. The gateway to guanine nucleotides: Allosteric regulation of IMP dehydrogenases. Protein Sci. 2022;31:e4399.","journal-title":"Protein Sci"},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"983490","DOI":"10.3389\/fimmu.2022.983490","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Zhang W, Zhou X, Liu L. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma. Front Immunol. 2022;13:983490.","journal-title":"Front Immunol"},{"key":"1427_CR8","doi-asserted-by":"publisher","first-page":"e24416","DOI":"10.1002\/jcla.24416","volume":"36","author":"X Jia","year":"2022","unstructured":"Jia X, Liu Y, Cheng Y, Wang Y, Kang H, Ma Z, Chen K. Inosine monophosphate dehydrogenase type1 sustains tumor growth in hepatocellular carcinoma. J Clin Lab Anal. 2022;36:e24416.","journal-title":"J Clin Lab Anal"},{"key":"1427_CR9","doi-asserted-by":"crossref","unstructured":"Lopez-Janeiro A, Ruz-Caracuel I, Ramon-Patino JL, De Los Rios V, Villalba Esparza M, Berjon A, Yebenes L, Hernandez A, Masetto I, Kadioglu E, Goubert V, Heredia-Soto V, Barderas R, Casal JI, de Andrea CE, Redondo A, Mendiola M, Pelaez-Garcia A, Hardisson D. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13040794"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"105234","DOI":"10.1016\/j.jprot.2024.105234","volume":"304","author":"M Ni","year":"2024","unstructured":"Ni M, Wan D, Wu J, Gong W, Wang J, Zheng Z. Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics. J Proteom. 2024;304:105234.","journal-title":"J Proteom"},{"key":"1427_CR11","doi-asserted-by":"crossref","unstructured":"Alberti-Valls M, Olave S, Olomi A, Macia A, Eritja N. Advances in immunotherapy for endometrial cancer: insights into MMR status and tumor microenvironment. Cancers (Basel). 2024;16.","DOI":"10.3390\/cancers16233918"},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"916689","DOI":"10.3389\/fmolb.2022.916689","volume":"9","author":"S Liu","year":"2022","unstructured":"Liu S, Zhang Q, Liu W, Huang X. Prediction of Prognosis in Patients With Endometrial Carcinoma and Immune Microenvironment Estimation Based on Ferroptosis-Related Genes. Front Mol Biosci. 2022;9:916689.","journal-title":"Front Mol Biosci"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2023.01.037","volume":"171","author":"K Dessources","year":"2023","unstructured":"Dessources K, Ferrando L, Zhou QC, Iasonos A, Abu-Rustum NR, Reis-Filho JS, Riaz N, Zamarin D, Weigelt B. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. Gynecol Oncol. 2023;171:15\u201322.","journal-title":"Gynecol Oncol"},{"key":"1427_CR14","doi-asserted-by":"crossref","unstructured":"Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S, Sasaki AT. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11091346"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41401-024-01411-8","volume":"46","author":"MM Zheng","year":"2025","unstructured":"Zheng MM, Li JY, Guo HJ, Zhang J, Wang LS, Jiang KF, Wu HH, He QJ, Ding L, Yang B. IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy. Acta Pharmacol Sin. 2025;46:1058\u201367.","journal-title":"Acta Pharmacol Sin"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1101\/gad.349359.122","volume":"36","author":"KD Sutherland","year":"2022","unstructured":"Sutherland KD, Ireland AS, Oliver TG. Killing SCLC: insights into how to target a shapeshifting tumor. Genes Dev. 2022;36:241\u201358.","journal-title":"Genes Dev"}],"container-title":["BMC Genomic Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12863-026-01427-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-026-01427-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-026-01427-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:53:40Z","timestamp":1781744020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12863-026-01427-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s12863-026-01427-5","relation":{},"ISSN":["2730-6844"],"issn-type":[{"value":"2730-6844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (Approval No. NFEC-2016-110). All procedures were conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines. Informed consent was obtained from all participants or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}